MPM Oncology Impact Management »

Forte Biosciences shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Forte Biosciences (FBRX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Forte Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Forte Biosciences held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Forte Biosciences by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $26M 1.0M 25.90

More positions owned by MPM Oncology Impact Management

DBV Technologies S A Sponsored Ads (DBVT)
Cullinan Therapeutics Common (CGEM)
Aktis Oncology Common (AKTS)
Liquidia Corporation Common (LQDA)
Alumis Common (ALMS)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Corcept Therapeutics Common (CORT)
Trevi Therapeutics Common (TRVI)
Dianthus Therapeutics Common (DNTH)
Xenon Pharmaceuticals Common (XENE)
MoonLake Immunotherapeutics Class A Ord (MLTX)
Travere Therapeutics Common (TVTX)
Evommune Common (EVMN)

View all positions for MPM Oncology Impact Management

Top funds holding Forte Biosciences

Federated Investors
Fred Alger Management
OrbiMed Advisors
Henderson Group
Affinity Asset Advisors
MPM Oncology Impact Management
Adage Capital Partners GP
Vanguard Capital Management
Morgan Stanley
Cable Car Capital
FMR
Millennium Management
Woodline Partners
Citadel Advisors
AWM Investment Company

View all funds holding Forte Biosciences